IGF-1 and prostate cancer

Research output: Chapter in Book/Report/Conference proceedingChapter

18 Citations (Scopus)

Abstract

By virtue of their potent proliferative and anti-apoptotic effects, the insulin-like growth factors (IGFs) have been the subject of long-term scrutiny for their role in tumorigenesis. With regard to prostate cancer in particular, IGF-1 has been shown to stimulate the proliferation of human prostate epithelial cells in culture and to be necessary for normal growth and development of the rat and mouse prostate. Epidemiological studies have established a link between high circulating serum IGF-1 levels and the risk of later developing advanced prostate cancer, and overexpression of IGF-1 in the prostate basal epithelial layer of transgenic mice results in prostate adenocarcinoma that is similar to human disease. Thus, IGF-1 action appears to be important for prostate cancer initiation. On the other hand, decreased IGF action, subsequent to the down-regulation of IGF-1 receptor expression, is associated with advanced, metastatic disease. This decrease in IGF-1 receptor may confer a survival advantage to prostate cancer cells that have entered the circulation by making them resistant to the differentiative effects of IGF-1 at metastatic sites such as bone. The molecular mechanisms that effect IGF-1 receptor down-regulation appear to involve novel oncogenic functions of the Wilms' tumour suppressor, as well as novel actions of the androgen receptor.

Original languageEnglish (US)
Title of host publicationNovartis Foundation Symposium
Pages193-204
Number of pages12
Volume262
StatePublished - 2004
Externally publishedYes

Publication series

NameNovartis Foundation Symposium
Volume262

Fingerprint

Somatomedins
Prostatic Neoplasms
Somatomedin Receptors
Prostate
Down-Regulation
Wilms Tumor
Androgen Receptors
Growth and Development
Transgenic Mice
Epidemiologic Studies
Carcinogenesis
Adenocarcinoma
Cell Culture Techniques
Epithelial Cells
Bone and Bones
Survival
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Roberts, C., & Holly (2004). IGF-1 and prostate cancer. In Novartis Foundation Symposium (Vol. 262, pp. 193-204). (Novartis Foundation Symposium; Vol. 262).

IGF-1 and prostate cancer. / Roberts, Charles; Holly.

Novartis Foundation Symposium. Vol. 262 2004. p. 193-204 (Novartis Foundation Symposium; Vol. 262).

Research output: Chapter in Book/Report/Conference proceedingChapter

Roberts, C & Holly 2004, IGF-1 and prostate cancer. in Novartis Foundation Symposium. vol. 262, Novartis Foundation Symposium, vol. 262, pp. 193-204.
Roberts C, Holly. IGF-1 and prostate cancer. In Novartis Foundation Symposium. Vol. 262. 2004. p. 193-204. (Novartis Foundation Symposium).
Roberts, Charles ; Holly. / IGF-1 and prostate cancer. Novartis Foundation Symposium. Vol. 262 2004. pp. 193-204 (Novartis Foundation Symposium).
@inbook{04590d3f76ae474f93db6a9ad2f24a43,
title = "IGF-1 and prostate cancer",
abstract = "By virtue of their potent proliferative and anti-apoptotic effects, the insulin-like growth factors (IGFs) have been the subject of long-term scrutiny for their role in tumorigenesis. With regard to prostate cancer in particular, IGF-1 has been shown to stimulate the proliferation of human prostate epithelial cells in culture and to be necessary for normal growth and development of the rat and mouse prostate. Epidemiological studies have established a link between high circulating serum IGF-1 levels and the risk of later developing advanced prostate cancer, and overexpression of IGF-1 in the prostate basal epithelial layer of transgenic mice results in prostate adenocarcinoma that is similar to human disease. Thus, IGF-1 action appears to be important for prostate cancer initiation. On the other hand, decreased IGF action, subsequent to the down-regulation of IGF-1 receptor expression, is associated with advanced, metastatic disease. This decrease in IGF-1 receptor may confer a survival advantage to prostate cancer cells that have entered the circulation by making them resistant to the differentiative effects of IGF-1 at metastatic sites such as bone. The molecular mechanisms that effect IGF-1 receptor down-regulation appear to involve novel oncogenic functions of the Wilms' tumour suppressor, as well as novel actions of the androgen receptor.",
author = "Charles Roberts and Holly",
year = "2004",
language = "English (US)",
volume = "262",
series = "Novartis Foundation Symposium",
pages = "193--204",
booktitle = "Novartis Foundation Symposium",

}

TY - CHAP

T1 - IGF-1 and prostate cancer

AU - Roberts, Charles

AU - Holly,

PY - 2004

Y1 - 2004

N2 - By virtue of their potent proliferative and anti-apoptotic effects, the insulin-like growth factors (IGFs) have been the subject of long-term scrutiny for their role in tumorigenesis. With regard to prostate cancer in particular, IGF-1 has been shown to stimulate the proliferation of human prostate epithelial cells in culture and to be necessary for normal growth and development of the rat and mouse prostate. Epidemiological studies have established a link between high circulating serum IGF-1 levels and the risk of later developing advanced prostate cancer, and overexpression of IGF-1 in the prostate basal epithelial layer of transgenic mice results in prostate adenocarcinoma that is similar to human disease. Thus, IGF-1 action appears to be important for prostate cancer initiation. On the other hand, decreased IGF action, subsequent to the down-regulation of IGF-1 receptor expression, is associated with advanced, metastatic disease. This decrease in IGF-1 receptor may confer a survival advantage to prostate cancer cells that have entered the circulation by making them resistant to the differentiative effects of IGF-1 at metastatic sites such as bone. The molecular mechanisms that effect IGF-1 receptor down-regulation appear to involve novel oncogenic functions of the Wilms' tumour suppressor, as well as novel actions of the androgen receptor.

AB - By virtue of their potent proliferative and anti-apoptotic effects, the insulin-like growth factors (IGFs) have been the subject of long-term scrutiny for their role in tumorigenesis. With regard to prostate cancer in particular, IGF-1 has been shown to stimulate the proliferation of human prostate epithelial cells in culture and to be necessary for normal growth and development of the rat and mouse prostate. Epidemiological studies have established a link between high circulating serum IGF-1 levels and the risk of later developing advanced prostate cancer, and overexpression of IGF-1 in the prostate basal epithelial layer of transgenic mice results in prostate adenocarcinoma that is similar to human disease. Thus, IGF-1 action appears to be important for prostate cancer initiation. On the other hand, decreased IGF action, subsequent to the down-regulation of IGF-1 receptor expression, is associated with advanced, metastatic disease. This decrease in IGF-1 receptor may confer a survival advantage to prostate cancer cells that have entered the circulation by making them resistant to the differentiative effects of IGF-1 at metastatic sites such as bone. The molecular mechanisms that effect IGF-1 receptor down-regulation appear to involve novel oncogenic functions of the Wilms' tumour suppressor, as well as novel actions of the androgen receptor.

UR - http://www.scopus.com/inward/record.url?scp=13244294871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13244294871&partnerID=8YFLogxK

M3 - Chapter

VL - 262

T3 - Novartis Foundation Symposium

SP - 193

EP - 204

BT - Novartis Foundation Symposium

ER -